Monitor for asset sale announcements or financing activities as cash runway is critically low at under $7.2 million; watch for Nasdaq delisting decision and potential uplisting of any partnerships or transactions from the strategic review.
Price Chart
Executive Summary
BioAtla reported Q4 2025 financial results with a net loss of $9.8 million, down from $14.9 million in the prior year, while cash dropped to $7.1 million from $49.0 million. The company initiated a formal strategic review to monetize assets, implemented a 70% workforce reduction, and faces Nasdaq delisting risk due to non-compliance with listing rules.
Key Financial Metrics
Key Facts
- Net loss for Q4 2025 was $9.8 million, improved from $14.9 million in Q4 2024
- Cash and cash equivalents declined sharply to $7.1 million as of December 31, 2025, from $49.0 million in 2024
- Company initiated a formal process to explore strategic options including asset sales and partnerships
- 70% workforce reduction announced with estimated severance costs of $0.5-$0.6 million
- Nasdaq has initiated delisting proceedings due to failure to meet $1.00 bid price and $2.5 million stockholders' equity requirements
- CFO Richard Waldron departed; Chris Vasquez appointed as new CFO
Financial Impact
Cash burn of $41.9 million in 2025; R&D expenses down 31% to $43.6 million; G&A down 19% to $17.7 million
Risk Factors
- Delisting risk from Nasdaq due to bid price and equity deficiencies
- Going concern uncertainty with cash of $7.1 million and history of significant losses
- Strategic review may result in unfavorable terms or no transaction
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-134501 |
| Document: bcab-ex99_2.htm | 0001193125-26-134501 |
| Document: bcab-20260331.htm | 0001193125-26-134501 |
| Document: 0001193125-26-134501-index-headers.html | 0001193125-26-134501 |
| Document: 0001193125-26-134501-index.html | 0001193125-26-134501 |
| Document: 0001193125-26-134501.txt | 0001193125-26-134501 |
| 8-K Data (Synthetic) | 0001193125-26-134501 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | S-1 | $1.74 | awaiting T+20 | — | $1.71 (+1.44%) |
Oct 19, 2026 6d ago | 8-K | $1.74 | awaiting T+20 | — | $1.71 (+1.44%) |
Aug 28, 2026 8w ago | 8-K | $1.74 $1.74 | · 0.00% | ▲ +0.26% | $1.71 (+1.44%) |
Mar 31, 2026 29w ago | 8-K | $6.75 $4.04 | ▲ +40.15% | ▲ +49.87% | $1.71 (+74.67%) |
Mar 2, 2026 34w ago | DEFA14A | $10.20 $7.70 | ▼ −24.51% | ▼ −16.57% | $1.71 (−83.24%) |
Mar 2, 2026 34w ago | Press Release | $10.20 $7.70 | ▲ +24.51% | ▲ +16.57% | $1.71 (+83.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers